EA200700176A1 - PEPTIDE, NORMALIZING METABOLISM IN BONE AND NURSING TISSUES, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND METHOD OF ITS APPLICATION - Google Patents

PEPTIDE, NORMALIZING METABOLISM IN BONE AND NURSING TISSUES, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND METHOD OF ITS APPLICATION

Info

Publication number
EA200700176A1
EA200700176A1 EA200700176A EA200700176A EA200700176A1 EA 200700176 A1 EA200700176 A1 EA 200700176A1 EA 200700176 A EA200700176 A EA 200700176A EA 200700176 A EA200700176 A EA 200700176A EA 200700176 A1 EA200700176 A1 EA 200700176A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bone
metabolism
pharmaceutical composition
tissues
cartilage tissues
Prior art date
Application number
EA200700176A
Other languages
Russian (ru)
Other versions
EA010574B1 (en
Inventor
Владимир Хацкелевич Хавинсон
Евгений Иосифович ГРИГОРЬЕВ
Владимир Викторович МАЛИНИН
Галина Анатольевна Рыжак
Original Assignee
Общество С Ограниченной Ответственностью "Сиа Пептайдс"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Сиа Пептайдс" filed Critical Общество С Ограниченной Ответственностью "Сиа Пептайдс"
Publication of EA200700176A1 publication Critical patent/EA200700176A1/en
Publication of EA010574B1 publication Critical patent/EA010574B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к лекарственным средствам для профилактики и лечения заболеваний опорно-двигательного аппарата, в частности дегенеративно-дистрофических заболеваний суставов и позвоночника, и может быть использовано как средство, нормализующее метаболизм в костной и хрящевой тканях. Предлагается фармацевтическая композиция, нормализующая метаболизм в костной и хрящевой тканях, содержащая в качестве активного начала эффективное количество пептида аланил-глутамил-аспарагиновая кислота общей формулы: H-Ala-Glu-Asp-OH последовательности 1 [SEQ ID NO:1] и фармацевтически приемлемый носитель. Предлагается пептид аланил-глутамил-аспарагиновая кислота общей формулы: H-hAla-Glu-Asp-OH последовательности 1 [SEQ ID NO:1], обладающий биологической активностью, проявляющейся в нормализации метаболизма в костной и хрящевой тканях. Предлагается способ профилактики и лечения заболеваний опорно-двигательного аппарата путем нормализации метаболизма в костной и хрящевой тканях, заключающийся во введении пациенту фармацевтической композиции, содержащей в качестве активного начала пептид аланил-глутамил-аспарагиновая кислота общей формулы: H-Ala-Glu-Asp-OH последовательности 1 [SEQ ID NO:1] в дозе 0,01-100 мкг/кг массы тела, по крайней мере один раз в день в течение периода, необходимого для достижения терапевтического эффекта.The invention relates to medicines for the prevention and treatment of diseases of the musculoskeletal system, in particular degenerative diseases of the joints and spine, and can be used as a means of normalizing metabolism in bone and cartilage tissues. A pharmaceutical composition is proposed that normalizes metabolism in bone and cartilage tissues, containing as an active principle an effective amount of an alanyl-glutamyl-aspartic acid peptide of the general formula: H-Ala-Glu-Asp-OH of sequence 1 [SEQ ID NO: 1] and a pharmaceutically acceptable carrier. An alanyl-glutamyl-aspartic acid peptide of the general formula: H-hAla-Glu-Asp-OH of sequence 1 [SEQ ID NO: 1] is proposed, which has biological activity that is manifested in the normalization of metabolism in bone and cartilage tissues. A method is proposed for the prevention and treatment of diseases of the musculoskeletal system by normalizing metabolism in the bone and cartilage tissues, which consists in administering to the patient a pharmaceutical composition containing, as an active principle, an alanyl-glutamyl-aspartic acid peptide of the general formula: H-Ala-Glu-Asp-OH sequence 1 [SEQ ID NO: 1] at a dose of 0.01-100 μg / kg body weight, at least once a day for the period necessary to achieve a therapeutic effect.

EA200700176A 2006-05-30 2007-01-29 Peptide normalizing netabolism in bone and cartilaginous tissues, pharmaceutical composition based thereon and method for use thereof EA010574B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2006118497/15A RU2299741C1 (en) 2006-05-30 2006-05-30 Peptide normalizing metabolism in osseous and cartilage tissue, pharmaceutical composition based on thereof and method for its using

Publications (2)

Publication Number Publication Date
EA200700176A1 true EA200700176A1 (en) 2007-12-28
EA010574B1 EA010574B1 (en) 2008-10-30

Family

ID=38310627

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700176A EA010574B1 (en) 2006-05-30 2007-01-29 Peptide normalizing netabolism in bone and cartilaginous tissues, pharmaceutical composition based thereon and method for use thereof

Country Status (3)

Country Link
EA (1) EA010574B1 (en)
RU (1) RU2299741C1 (en)
WO (1) WO2007139433A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2496511C1 (en) * 2012-04-20 2013-10-27 Замертон Холдингс Лимитед Pharmaceutical composition, agent (versions) and method of preventing and treating arthritis, osteoarthrosis and vertebral osteochondrosis (versions)
EA018614B1 (en) * 2012-11-15 2013-09-30 Замертон Холдингс Лимитед Pharmaceutical composition for treating prostatic hyperplasia, use thereof and method for treating prostatic hyperplasia
RU2521973C1 (en) * 2013-08-23 2014-07-10 Замертон Холдингс Лимитед Method for preventing and treating arthropathies and methods for using same
EA025549B1 (en) 2014-09-09 2017-01-30 Замертон Холдингс Лимитед Composition and agents for prevention and treatment of diseases of the joints and the spine, and methods of their application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101850120A (en) * 1999-07-21 2010-10-06 奥默罗斯公司 Be used for inhibition of pain, the solution of inflammation and cartilage degradation and method

Also Published As

Publication number Publication date
WO2007139433A1 (en) 2007-12-06
EA010574B1 (en) 2008-10-30
WO2007139433A8 (en) 2009-07-16
RU2299741C1 (en) 2007-05-27

Similar Documents

Publication Publication Date Title
EA201270144A1 (en) COMBINED THERAPY FOR TREATMENT OF DIABETES
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
EP2331095A4 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112014015482A8 (en) phenyl carbamate compounds for use in the alleviation or treatment of pain and neuropathic pain
BR112013005673A2 (en) use of lysosomal acid lipase for treatment of lysosomal acid lipase deficiency in patients
JP6363952B2 (en) Use of growth hormone fragments
KR20190101990A (en) Composition comprising the peptide WKDEAGKPLVK
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
EP1369119B1 (en) Il-12 expression controlling agents
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
UA98462C2 (en) Methods for treating autoimmune diseases using a taci-ig fusion molecule
MX2008013635A (en) Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders.
EA200700176A1 (en) PEPTIDE, NORMALIZING METABOLISM IN BONE AND NURSING TISSUES, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND METHOD OF ITS APPLICATION
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
DK2032595T3 (en) Peptide substance having an immuno-protective effect, the pharmaceutical composition thereof and its method of use.
EP3508201A3 (en) Glycine as a diet supplement for use in the treatment skin problems that result from underlying collagen disorders and and cosmetic uses thereof
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
UA91136C2 (en) Peptide capable of stimulating the regeneration of neurons, pharmaceutical composition based thereon and method of use thereof
EA200601581A1 (en) PEPTIDE, STIMULATING LIVER TISSUE REGENERATION, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND ITS APPLICATION
RU2007143337A (en) PHARMACEUTICAL COMPOSITION BASED ON A PEPTIDE REGULATING AN ANGIOGENESIS DISORDER, AND METHOD OF ITS APPLICATION
JP6434650B2 (en) New use of isoquinoline derivatives for the treatment of diabetic wounds
Yu et al. Creatine derivatives: rapid complete relief of pain by topical or transcutaneous administration
RU2012114097A (en) THERAPEUTIC AGENT AGAINST CHRONIC PAIN

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TM

PC4A Registration of transfer of a eurasian patent by assignment